ArticleClinical medicine insights. Pediatrics2026
Assessment of Serum Interleukins 18 and 22 in Predicting Neonatal Sepsis and Mortality: A Case-Control Study.
Article in Clinical medicine insights. Pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is a leading cause of neonatal morbidity and mortality, but its early diagnosis remains challenging. Neonatal sepsis (NS) induces an immune response with the release of Inflammatory cytokines, which may serve as early diagnostic biomarkers. Limited data indicate interleukin (IL)-18 and IL-22 levels are elevated in NS and associated with mortality. Objectives: To investigate the diagnostic performance of serum IL-18 and IL-22 levels in predicting NS and mortality. Design: Case-control study. Methods: We enrolled 55 newborns with culture-positive sepsis and 34 age- and sex-matched healthy controls. Serum IL-18 and IL-22 levels were measured using enzyme-linked immunosorbent assay. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic performance of IL-18 and IL-22 in predicting NS and mortality. Results: Compared with controls, newborns with NS had significantly higher median levels of IL-18 (910 vs 256 pg/mL, Conclusion: IL-18 and IL-22 are potentially promising biomarkers for identifying NS and predicting neonatal mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.